Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases

References

• Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37.
   PubMed Web of Science ®Google Scholar
• Stepanov A, Karelina T, Markevich N, et al. A mathematical model of multisite phosphorylation of tau protein. PLoS ONE. 2018;13:e0192519.
   PubMed Web of Science ®Google Scholar
• Edelstein-Keshet L, Spiros A. Exploring the formation of Alzheimer’s disease senile plaques in silico. J Theor Biol. 2002;216:301–326.
   PubMed Web of Science ®Google Scholar
• Liu F, Liang Z, Shi J, et al. PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Letters. 2006;580:6269–6274.
   PubMed Web of Science ®Google Scholar
• Liu F, Liang Z, Gong CX. Hyperphosphorylation of tau and protein phosphatases in Alzheimer disease. Panminerva Med. 2006;48:97–108.
   PubMed Web of Science ®Google Scholar
• Geerts H. Of mice and men: bridging the translational disconnect in CNS drug discovery. CNS Drugs. 2009;23:915–926.
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–185.
   PubMed Web of Science ®Google Scholar
• Geerts H, Spiros A, Roberts P. Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model. Alzheimers Res Ther. 2018;10:14.
   PubMed Web of Science ®Google Scholar
• Bischoff KB. Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy. Cancer Chemother Rep. 1975;59:777–793.
   PubMedGoogle Scholar
• Liu J, Ogden A, Comery TA, et al. Prediction of efficacy of vabicaserin, a 5-HT2C agonist, for the treatment of schizophrenia using a quantitative systems pharmacology model. CPT Pharmacometrics Syst Pharmacol. 2014;3:e111.
   PubMedGoogle Scholar
• Van Maanen EMT, Van Steeg TJ, Ahsman MJ, et al. Extending a systems model of the app pathway: separation of beta- and gamma-secretase sequential cleavage steps of APP. J Pharmacol Exp Ther. 2018;365:507–518.
   PubMed Web of Science ®Google Scholar
• Hines ML, Carnevale NT. The NEURON simulation environment. Neural Comput. 1997;9:1179–1209.
   PubMed Web of Science ®Google Scholar
• Maciukiewicz M, Marshe VS, Hauschild AC, et al. GWAS-based machine learning approach to predict duloxetine response in major depressive disorder. J Psychiatr Res. 2018;99:62–68.
   PubMed Web of Science ®Google Scholar
• Peck RW. Strategies in selecting an agent for clinical trials. Ann N Y Acad Sci. 1997;823:319–327.
   PubMed Web of Science ®Google Scholar
• Holford NH, Kimko HC, Monteleone JP, et al. Simulation of clinical trials. Annu Rev Pharmacol Toxicol. 2000;40:209–234.
   PubMed Web of Science ®Google Scholar
• Kimko H, Pinheiro J. Model-based clinical drug development in the past, present and future: a commentary. Br J Clin Pharmacol. 2015;79:108–116.
   PubMed Web of Science ®Google Scholar
• Lockwood P, Ewy W, Hermann D, et al. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer’s disease. Pharm Res. 2006;23:2050–2059.
   PubMed Web of Science ®Google Scholar
• Mandema JW, Gibbs M, Boyd RA, et al. Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond. Clin Pharmacol Ther. 2011;90:766–769.
   PubMed Web of Science ®Google Scholar
• Niva C, Parkinson J, Olsson F, et al. Has inhibition of Abeta production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of gamma-secretase inhibitor data. Eur J Clin Pharmacol. 2013;69:1247–1260.
   PubMed Web of Science ®Google Scholar
• Fisher PM, Holst KK, Mc Mahon B, et al. 5-HTTLPR status predictive of neocortical 5-HT4 binding assessed with [(11)C]SB207145 PET in humans. NeuroImage. 2012;62:130–136.
   PubMed Web of Science ®Google Scholar
• Klinke DJ 2nd. Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: interleukin-12 as a case study. J Immunother Cancer. 2015;3:27.
   PubMed Web of Science ®Google Scholar
• Cherkaoui-Rbati MH, Paine SW, Littlewood P, et al. A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions. PLoS ONE. 2017;12:e0183794.
   PubMed Web of Science ®Google Scholar
• Gupta S, Kihara Y, Maurya MR, et al. Computational modeling of competitive metabolism between omega3- and omega6-polyunsaturated fatty acids in inflammatory macrophages. J Phys Chem B. 2016;120:8346–8353.
   PubMed Web of Science ®Google Scholar
• Woodhead JL, Watkins PB, Howell BA, et al. The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury. Drug Metab Pharmacokinet. 2017;32:40–45.
   PubMed Web of Science ®Google Scholar
• Geerts H, Spiros A, Roberts P, et al. Has the time come for predictive computer modeling in CNS drug discovery and development? CPT Pharmacometrics Syst Pharmacol. 2012;1:e16.
   PubMedGoogle Scholar
• Geerts H, Spiros A, Roberts P, et al. Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development. J Pharmacokinet Pharmacodyn. 2013;40:257–265.
   PubMed Web of Science ®Google Scholar
• Geerts H, Spiros A, Roberts P, et al. Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response. PLoS ONE. 2012;7:e49732.
   PubMed Web of Science ®Google Scholar
• Nicholas T, Duvvuri S, Leurent C, et al. Systems pharmacology modeling in neuroscience: prediction and outcome of PF-04995274, a 5HT4 partial agonist, in a clinical scopolamine. Impairment Trial Advances in Alzheimer’s Disease. 2013;2:83–98.
   Google Scholar
• Geerts H, Roberts P, Spiros A, et al. Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: application to iloperidone. J Psychopharmacol. 2015;29:372–382.
   PubMed Web of Science ®Google Scholar
• Chan PL, Holford NH. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol. 2001;41:625–659.
   PubMed Web of Science ®Google Scholar
• Liu X, Tsai WY, Stern Y. A functional decline model for prevalent cohort data. Statistics in Medicine. 1996;15:1023–1032.
   PubMed Web of Science ®Google Scholar
• Delor I, Charoin JE, Gieschke R, et al. Modeling Alzheimer’s disease progression using disease onset time and disease trajectory concepts applied to CDR-SOB scores from ADNI. CPT: Pharmacometrics & Systems Pharmacology. 2013;2:e78.
   PubMedGoogle Scholar
• Rogers JA, Polhamus D, Gillespie WR, et al. Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis. J Pharmacokinet Pharmacodyn. 2012;39:479–498.
   PubMed Web of Science ®Google Scholar
• Romero K, Ito K, Rogers JA, et al. The future is now: model-based clinical trial design for Alzheimer’s disease. Clin Pharmacol Ther. 2015;97:210–214.
   PubMed Web of Science ®Google Scholar
• Iturria-Medina Y, Sotero RC, Toussaint PJ, et al. Epidemic spreading model to characterize misfolded proteins propagation in aging and associated neurodegenerative disorders. PLoS Comput Biol. 2014;10:e1003956.
   PubMed Web of Science ®Google Scholar
• Umbricht D, Alberati D, Martin-Facklam M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014;71:637–646.
   PubMed Web of Science ®Google Scholar
• Spiros A, Roberts P, Geerts H. A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance. Front Pharmacol. 2014;5:229.
   PubMed Web of Science ®Google Scholar
• Geerts H, Roberts P, Spiros A. Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology. Front Pharmacol. 2015;6:198.
   PubMed Web of Science ®Google Scholar
• Lim YY, Maruff P, Schindler R, et al. Disruption of cholinergic neurotransmission exacerbates Abeta-related cognitive impairment in preclinical Alzheimer’s disease. Neurobiology of Aging. 2015;36:2709–2715.
   PubMed Web of Science ®Google Scholar
• Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Molecular Psychiatry. 2008;14:804–819.
   PubMed Web of Science ®Google Scholar